An article on investment blog Seeking Alpha highlights some recent problems facing pharmaceutical giant Eli Lilly, which potential investors might want to consider.
According to the blog, test results for a new schizophrenia drug proved disappointing. So much so that the company halted research into the product.
A new treatment for Alzheimer’s proved only partially effective against a mild form of the disease, and useless in most cases. A recent study also ...
continue reading...